IGC Pharma
29 hedge funds and large institutions have $1.73M invested in IGC Pharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 4 closing their positions.
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
345% more call options, than puts
Call options by funds: $236K | Put options by funds: $53K
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.87% less ownership
Funds ownership: 8.2% → 6.33% (-1.9%)
56% less capital invested
Capital invested by funds: $3.97M → $1.73M (-$2.24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$137K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$75.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.9K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$31.7K |
| 5 |
Jane Street
New York
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.31M |
| 2 |
BlackRock
New York
|
-$72.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$14K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| 5 |
FFA
Fairfield Financial Advisors
Wellesley,
Massachusetts
|
-$474 |
IGC Hedge Fund Activity: Q2 2022 in Review
29 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2022, worth a combined $1.73M — down 56% from $3.97M a quarter earlier.
Fund positioning in IGC was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 13 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $137K. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $1.31M sold.
- 29 institutional investors held IGC Pharma (IGC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.73M of IGC Pharma stock for Q2 2022, down 56% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q2 2022 was Renaissance Technologies, an estimated $137K added.
- The largest IGC Pharma seller in Q2 2022 was Mirae Asset Global Investments, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2022.